A Randomized Crossover TrIal to Compare Recombinant Human rhPTH(1-34) to the ASsociation Alfacalcidol/Hydrochlorothiazide in the Treatment of Autosomal Dominant Hypocalcemia

Trial Profile

A Randomized Crossover TrIal to Compare Recombinant Human rhPTH(1-34) to the ASsociation Alfacalcidol/Hydrochlorothiazide in the Treatment of Autosomal Dominant Hypocalcemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Teriparatide (Primary) ; Alfacalcidol; Amiloride; Hydrochlorothiazide
  • Indications Hypocalcaemia
  • Focus Therapeutic Use
  • Acronyms ACTICAS
  • Most Recent Events

    • 19 Jun 2017 Planned End Date changed from 1 Nov 2019 to 1 Aug 2020.
    • 19 Jun 2017 Planned primary completion date changed from 1 Nov 2019 to 1 Aug 2020.
    • 07 Oct 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top